Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic VSL#3 for visceral hypersensitivity in irritable bowel syndrome
2007-000008-34Phase 4Terminated
- Sponsor
- North West London Hospitals NHS Trust
- Start
- May 2007
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of VSL#3 in irritable bowel syndrome (IBS), sponsored by North West London Hospitals NHS Trust. Primary endpoint: Change in physiological rectal sensitivity. Started May 2007; status: terminated.
02
Drugs
VSL#3
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2007-000008-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000008-34.